GEO DataSet Links for BioProject (Select 232711) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from BioProject

Items: 2

Select item 2000537161.

IFNb-1a in-vivo treatment induces the expression and signaling of IFNAR1 and inhibits Th17 responses in PBMCs derived from CIS patients

(Submitter supplied) IFNb has been used as a first line therapy for relapsing remitting multiple sclerosis (RRMS). Since only a few studies have addressed the role of endogenous IFNb in the pathogenesis of the disease, our objective was to characterize its role in the transcriptional regulation of pathogenic Th17 cytokines in patients with RRMS. In-vitro studies have demonstrated that IFNb inhibited IL-17A, IL-17F, IL-21, IL-22 and IFN-b secretion in CD4+ lymphocytes through the induction of suppressor of cytokine secretion (SOCS)1 and 3. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4994
Platform:: GPL570
12 Samples

Download data: CEL

Series

Accession:: GSE53716

ID:: 200053716

Select item 49942.

IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells

Analysis of PBMCs from patients with clinically isolated syndrome suggestive of multiple sclerosis (CIS) after 12 months of IFNβ-1a treatment. All patients exhibited a favorable response to IFN-β-1a treatment. Results provide insight into the role of endogenous IFN-β in the pathogenesis of MS.